Quick Answer
Larimar Therapeutics, Inc. reported Research And Development Expense of $154.22 million for the year ending 2025.
- Larimar Therapeutics, Inc. showed an increase of +110.5% in Research And Development Expense from 2024 to 2025.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Larimar Therapeutics, Inc.'s Research And Development Expense has grown by 1,236.0%.
- Historical annual values: Fiscal year 2025: $154.22 million | Fiscal year 2024: $73.28 million | Fiscal year 2023: $27.67 million | Fiscal year 2022: $24.25 million | Fiscal year 2021: $38.40 million | Fiscal year 2020: $31.41 million | Fiscal year 2019: $20.79 million | Fiscal year 2018: $47.93 million | Fiscal year 2017: $40.84 million | Fiscal year 2016: $39.94 million | Fiscal year 2015: $54.62 million | Fiscal year 2014: $27.39 million | Fiscal year 2013: $9.56 million | Fiscal year 2012: $11.54 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: